76.00
0.13 (0.17%)
| Previous Close | 75.87 |
| Open | 74.65 |
| Volume | 510,259 |
| Avg. Volume (3M) | 462,073 |
| Market Cap | 2,208,398,080 |
| Price / Sales | 10.02 |
| Price / Book | 88.95 |
| 52 Weeks Range | |
| Earnings Date | 24 Feb 2026 |
| Profit Margin | -52.34% |
| Operating Margin (TTM) | -40.96% |
| Diluted EPS (TTM) | -3.12 |
| Quarterly Revenue Growth (YOY) | 11.30% |
| Total Debt/Equity (MRQ) | 585.48% |
| Current Ratio (MRQ) | 3.36 |
| Operating Cash Flow (TTM) | -68.09 M |
| Levered Free Cash Flow (TTM) | -44.94 M |
| Return on Assets (TTM) | -11.43% |
| Return on Equity (TTM) | -186.68% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Establishment Labs Holdings Inc | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.13 |
|
Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing silicone-filled breast and body shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 10.75% |
| % Held by Institutions | 106.06% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Jw Asset Management, Llc | 31 Dec 2025 | 3,061,694 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 100.00 (Mizuho, 31.58%) | Buy |
| Median | 88.00 (15.79%) | |
| Low | 74.00 (Citigroup, -2.63%) | Hold |
| Average | 86.86 (14.29%) | |
| Total | 6 Buy, 1 Hold | |
| Avg. Price @ Call | 76.29 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 11 Mar 2026 | 74.00 (-2.63%) | Hold | 66.24 |
| Canaccord Genuity | 26 Feb 2026 | 90.00 (18.42%) | Buy | 77.15 |
| 17 Dec 2025 | 85.00 (11.84%) | Buy | 74.71 | |
| Mizuho | 25 Feb 2026 | 100.00 (31.58%) | Buy | 78.29 |
| 17 Dec 2025 | 90.00 (18.42%) | Buy | 74.71 | |
| Stephens & Co. | 25 Feb 2026 | 90.00 (18.42%) | Buy | 78.29 |
| BTIG | 24 Feb 2026 | 88.00 (15.79%) | Buy | 79.67 |
| 31 Dec 2025 | 86.00 (13.16%) | Buy | 72.88 | |
| Needham | 24 Feb 2026 | 86.00 (13.16%) | Buy | 79.67 |
| 12 Jan 2026 | 84.00 (10.53%) | Buy | 66.76 | |
| JP Morgan | 17 Dec 2025 | 80.00 (5.26%) | Buy | 74.71 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Jan 2026 | Announcement | Establishment Labs Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025 |
| 31 Dec 2025 | Announcement | Establishment Labs to Present at 44th Annual J.P. Morgan Healthcare Conference |
| 29 Dec 2025 | Announcement | Establishment Labs Submits to FDA for Approval of Motiva Implants in Breast Reconstruction |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |